NCT04699032View on ClinicalTrials.gov

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

July 5, 2021

Study Completion Date

July 5, 2021

Conditions
Chronic Kidney Disease
Interventions
DRUG

Apraglutide

Single dose of apraglutide 5 mg.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

55114

Prism Clinical Research, Inc., Saint Paul

All Listed Sponsors
lead

VectivBio AG

INDUSTRY

NCT04699032 - Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function. | Biotech Hunter | Biotech Hunter